thalidomide has been researched along with Pulmonary Disease, Chronic Obstructive in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc." | 4.90 | [Progress in PDE4 targeted therapy for inflammatory diseases]. ( Song, SD; Tang, HF, 2014) |
| "Drugs for chronic obstructive pulmonary disease, cystic fibrosis, and diabetes have been used for several years." | 1.62 | Modification of Apremilast from Pills to Aerosol a Future Concept. ( Freitag, L; Hohenforst-Schmidt, W; Huang, H; Kosmidis, C; Kougkas, N; Lallas, A; Petridis, D; Sardeli, C; Zarogoulidis, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodimuthali, A | 1 |
| Jabaris, SS | 1 |
| Pal, M | 1 |
| Zarogoulidis, P | 1 |
| Kosmidis, C | 1 |
| Kougkas, N | 1 |
| Lallas, A | 1 |
| Petridis, D | 1 |
| Hohenforst-Schmidt, W | 1 |
| Huang, H | 1 |
| Freitag, L | 1 |
| Sardeli, C | 1 |
| Song, SD | 1 |
| Tang, HF | 1 |
| Braddock, M | 1 |
| Murray, C | 1 |
2 reviews available for thalidomide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chr | 2008 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; I | 2014 |
2 other studies available for thalidomide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Modification of Apremilast from Pills to Aerosol a Future Concept.
Topics: Administration, Inhalation; Aerosols; Humans; Nebulizers and Vaporizers; Particle Size; Pulmonary Di | 2021 |
10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Clinical Trials as Topic; Drug Delivery Systems; Drug Des | 2006 |